Ad Hoc Announcement Pursuant to Art. 53 LR

根据《上市规则》第53条发布的临时公告

Geneva, Switzerland, November 11, 2026

2026年11月11日，瑞士日内瓦

-

-

Addex Therapeutics

艾德克斯治疗公司

(SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has closed a $105 million Series B financing from a syndicate of leading life science investors.

（股票代码：SIX 和 Nasdaq: ADXN）是一家处于临床阶段的生物制药公司，专注于开发用于治疗神经系统疾病的新型小分子变构调节剂产品组合。该公司今日宣布，其分拆子公司 Neurosterix 已完成由一群领先的生命科学投资者组成的银团提供的 1.05 亿美元 B 轮融资。

Addex did not participate in the financing and its equity interest now represents 8.5% of the issued capital at a valuation of $18.6 million. .

Addex未参与此次融资，其股权现在占已发行股本的8.5%，估值为1,860万美元。

The proceeds raised will support mainly the planned Phase 2 clinical development of NTX-253, a highly selective muscarinic M4 positive allosteric modulator (PAM), for schizophrenia. The financing will also support Neurosterix’s broader pipeline of selective allosteric modulators for a range of neuropsychiatric disorders..

募集的资金将主要用于支持 NTX-253（一种高选择性毒蕈碱 M4 阳性变构调节剂）针对精神分裂症的计划中二期临床开发。此次融资还将支持 Neurosterix 更广泛的、针对多种神经精神疾病的选择性变构调节剂产品管线。

“The closing of this significant financing is a huge endorsement of the allosteric approach pioneered by Addex in schizophrenia as well as other neuropsychiatric disorders. Congatulations to the whole Neurosterix team, which has made enormous strides in advancing lead program NTX-253 through clinical development and ready for Phase 2, following our spin-out in 2024,” said Tim Dyer, CEO of Addex..

“此次重大融资的完成，是对Addex在精神分裂症及其他神经精神疾病领域开创的变构调节方法的高度认可。祝贺Neurosterix整个团队，自2024年我们分拆以来，该团队在推动先导项目NTX-253的临床开发方面取得了巨大进展，使其已准备好进入二期临床试验。”Addex首席执行官Tim Dyer表示。

About NTX-253 and M4 PAMs

关于NTX-253和M4 PAMs

The M4 muscarinic receptor is a validated target for treating schizophrenia and related disorders through indirect modulation of dopamine signaling. NTX-253 is a potent, highly selective, oral PAM of M4 that fine-tunes muscarinic signaling in the brain to potentially reduce psychosis symptoms while avoiding the movement disorders and metabolic complications associated with traditional dopamine antagonists.

M4毒蕈碱受体是通过间接调节多巴胺信号通路治疗精神分裂症及相关疾病的一个经验证靶点。NTX-253是一种强效、高选择性的口服M4正变构调节剂（PAM），能够精细调控大脑中的毒蕈碱信号传导，从而在避免与传统多巴胺拮抗剂相关的运动障碍和代谢并发症的同时，潜在地减轻精神病症状。

Neurosterix has completed Phase 1 single- and multiple-ascending-dose clinical studies of NTX-253, which data supporting advancing into larger scale Phase 2 clinical studies..

Neurosterix 已完成 NTX-253 的 I 期单次和多次递增剂量临床研究，相关数据支持其进入更大规模的 II 期临床研究。

About Neurosterix

关于 Neurosterix

Neurosterix is a clinical-stage biotechnology company focused on transforming neuropsychiatric care through selective allosteric modulation. The company’s approach is designed to fine-tune brain signaling with greater precision and selectivity, with the goal of developing safer, more effective treatments for people living with schizophrenia, and mood and anxiety disorders.

Neurosterix 是一家处于临床阶段的生物技术公司，专注于通过选择性变构调节来变革神经精神疾病的治疗。该公司的方法旨在以更高的精确度和选择性微调大脑信号传导，目的是为精神分裂症、情绪障碍和焦虑症患者开发更安全、更有效的治疗方法。

Neurosterix’s pipeline includes NTX-253, a selective muscarinic M4 positive allosteric modulator (PAM) for schizophrenia; NTX-819, a potentially first-in-class mGlu7 negative allosteric modulator (NAM) for mood and anxiety disorders; and NTX-529, a second differentiated M4 PAM for additional psychosis- and mood-related disorders.

Neurosterix的产品管线包括：NTX-253，一种用于精神分裂症的选择性毒蕈碱M4受体正向变构调节剂（PAM）；NTX-819，一种用于情绪和焦虑障碍的潜在首创新药机制的mGlu7受体负向变构调节剂（NAM）；以及NTX-529，第二种具有差异化的M4受体正向变构调节剂，用于其他精神病性和情绪相关疾病。

Neurosterix has operations in Boston and Geneva. For more information, visit www.neurosterix.com..

Neurosterix 在波士顿和日内瓦设有分支机构。欲了解更多信息，请访问 www.neurosterix.com。

About Addex Therapeutics

关于 Addex Therapeutics

Addex Therapeutics

Addex Therapeutics

is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery.

是一家临床阶段的生物制药公司，专注于开发用于神经系统疾病的新型小分子变构调节剂产品组合。Addex 的主要候选药物 dipraglurant（mGlu5 负性变构调节剂，NAM）正在评估其未来在脑损伤恢复（包括卒中后和创伤性脑损伤恢复）方面的开发潜力。

Addex has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. In addition, Addex  is advancing a differentiated GABAB PAM compound for the treatment of chronic cough. Addex holds a 8.5% equity interest in a private spin out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders and mGlu7 NAM for mood disorders.

Addex 已选择一款 GABAB 正向变构调节剂（PAM）候选药物，用于开发治疗物质使用障碍，并已成功完成新药临床试验申请（IND）所需的 enabling 研究。此外，Addex 正在推进一种具有差异化的 GABAB PAM 化合物，用于治疗慢性咳嗽。Addex 持有私人分拆公司 Neurosterix US Holdings LLC 8.5% 的股权，该公司正在推进一系列变构调节剂项目，包括用于精神分裂症、精神病和情绪相关障碍的 M4 PAM，以及用于情绪障碍的 mGlu7 负向变构调节剂（NAM）。

Addex has also invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders..

Addex 还投资了 Stalicla，这是一家瑞士私营公司，率先采用精准医学方法治疗神经发育障碍和神经精神疾病。

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit

Addex 的股份在瑞士 SIX 证券交易所上市，其美国存托股份（ADS）在纳斯达克资本市场上市，并在两家交易所均以股票代码“ADXN”进行交易。欲了解更多信息，请访问

www.addextherapeutics.com

www.addextherapeutics.com

.

。

Contacts:

联系人：

Tim Dyer

蒂姆·戴尔

Chief Executive Officer

首席执行官

Telephone: +41 22 884 15 55

电话：+41 22 884 15 55

PR@addextherapeutics.com

PR@addextherapeutics.com

Mike Sinclair

迈克·辛克莱尔

Partner, Halsin Partners

合伙人，Halsin Partners

+44 (0)7968 022075

+44 (0)7968 022075

msinclair@halsin.com

msinclair@halsin.com

Addex Forward Looking Statements:

Addex前瞻性声明：

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

本新闻稿包含经修订的《1995年私人证券诉讼改革法案》所定义的前瞻性陈述，包括关于本次发行募集资金预期用途的陈述。“可能”、“将”、“可以”、“会”、“应当”、“预期”、“计划”、“预计”、“打算”、“相信”、“估计”、“预测”、“规划”、“潜在”、“继续”、“目标”以及类似表述旨在识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别词语。

Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions.

本新闻稿中的任何前瞻性陈述均基于管理层当前的预期和信念，并受多种风险、不确定性和重要因素的影响，这些因素可能导致实际事件或结果与本新闻稿中任何前瞻性陈述所表达或暗示的内容存在重大差异，包括但不限于与市场状况相关的不确定性。

These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Addex Therapeutics' Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

上述及其他风险与不确定性在Addex Therapeutics的20-F表格年度报告、招股说明书以及该公司未来可能向美国证券交易委员会（SEC）提交的其他文件中的“风险因素”章节中有更详细的描述。本新闻稿中包含的任何前瞻性陈述仅反映Addex Therapeutics截至本文发布之日的观点，不应被视为代表其在任何后续日期的观点。

Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements..

Addex Therapeutics 明确声明不承担任何更新前瞻性陈述的义务。